Abstract 1833
Background
Although the personalized medicine has always focused on the genomic or proteomic characterization of tumor, medical imaging is still one of the major factors to guide therapy and to monitor the progression of the tumor. Radiomics is an emerging field that converts the medical image data into the mineable quantitative features via the automatically algorithms, and can server as a bridge between medical image, genomics and clinical-parameters. Serval studies have demonstrated that the radiomic-based model can predict outcome of RCC, but the correlation between radiomic features and histological subtypes of RCC is still unknown. The aim of this letter is to focus on the ability of radiomics to identify the histological subtypes and metastasis of RCC.
Methods
This study included Forty-four patients diagnosed with renal tumor. For each renal lesion, The CT images of volume of interest (VOI) were obtained semi-automatically by two experienced nuclear medicine physician, 85 texture features were extracted from each VOI using the first-order statistics features, Shape Based Features, Gray Level Neighboring Gray Level Dependence Matrix and Neighboring Gray Tone Difference Matrix.
Results
To investigate the value of radiomic features to capture phenotypic differences of RCC, we performed Unsupervised Clustering of patients with similar radiomic expression patterns. We analyzed the two main clusters of patients with clinical parameters, and found that the tumor clusters were statistically and significantly associated with primary tumor stage (P < 0.001), M-stage (P = 0.049) and benign (P = 0.037), wherein high T-stages, M-stage and tumor group showed in cluster II. RCC histology and N-stage (lymph-node) did not reach statistical significance for their association with the radiomic expression patterns (P = 0.165, 0.361, respectively). In addition, we analyzed the overall survival (OS) of the each radiomic features, and showed that P25, IMC1 and IMC2 were associated with OS (P = 0.002, 0.002, 0.016, respectively, log-rank test).
Conclusions
The radiomic features from medical images could be helpful in deciphering T-stages, metastasis and benign of RCC and may have potential as imaging biomarker for prediction of RCC overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
National Natural Science Foundation of China (No 81402117, 81671775), Natural Science Foundation of Zhejiang Province (No LY17H160043) and Qianjiang talent plan of Zhejiang Province (No QJD1602025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract